Drug firm Lupin Tuesday said it has received four observations in the establishment inspection report (EIR) given by the US health regulator following the closure of pharmacovigilance inspection. "The inspection included a comprehensive scrutiny of practices and procedures for reporting of adverse events of Lupin's marketed products worldwide. The inspection closed with four observations," the company said in a regulatory filing. Lupin has received the EIR from the United States Food and Drug Administration (USFDA) for the post-marketing adverse drug experience (PADE) inspection, indicating successful closure of the inspection, the filing added. The inspection was conducted at its global pharmacovigilance group DSRM (Drug Safety & Risk Management) based out of Mumbai between January 14-18, 2019, Lupin said. The USFDA issues an EIR to an establishment that is the subject of an FDA or FDA-contracted inspection following the closure of the inspection. Shares of Lupin Ltd were trading
from Latest News http://bit.ly/2Q8gc20
https://ift.tt/eA8V8J http://bit.ly/2SdCH5P
Home
Business
Business News
Business Standard
Latest News
Lupin gets four observations from USFDA for pharmacovigilance inspection
Tuesday, May 14, 2019
Related Posts:
Renault's Jean-Dominique Senard may replace Ghosn on Nissan board: ReportCarlos Ghosn's arrest and subsequent indictment on three charges expos… Read More
Cobrapost impact: Wadhawan group to bring strategic investor for DHFLDeal likely in 90 days, they say; promoter holding to be diluted on ex… Read More
This speciality chemicals stock zoomed 1700% in 5-years; hits new highAarti Industries hit a new high of Rs 1,714, rallying 1704 per cent in… Read More
Can't disclose black money reports as Par Panel examining them: FinMinIt denied to share the copies of these reports, saying the disclosure … Read More
0 comments: